Premium
Therapy‐related leukaemia cutis: A review
Author(s) -
Weinel Sarah,
Malone Janine,
Jain Dharamvir,
Callen Jeffrey P
Publication year - 2008
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/j.1440-0960.2008.00466.x
Subject(s) - medicine , cutis , myeloid leukaemia , chronic myeloid leukaemia , leukemia cutis , chemotherapy , malignancy , regimen , dermatology , immunology , leukemia
SUMMARY Leukaemia cutis following chemotherapy for a malignancy is a multifactorial process that is dependent on the chemotherapeutic agent used, the dosing regimen, and the cumulative dose as well as potential contributing therapies such as radiation and possibly even haematopoeitic support from granulocyte colony stimulating factor. In the right combination and in a patient with a conducive milieu of epigenetic factors, leukaemia can develop as a treatment complication. Leukaemia cutis is the specific infiltration of the skin by leukaemic cells and occurs most commonly when the underlying leukaemia is an acute myeloid leukaemia. Although it is well reviewed in the literature as a result of primary leukaemia, leukaemia cutis has only very rarely been reported in association with therapy‐induced leukaemia. This article reviews the factors that contribute to therapy‐related leukaemia and the development of leukaemia cutis.